



PATIENT • DOSAGE • COMPLIANCE



AUGMERO- 1GM
Injection

AUGMERO- 1GM

Meropenem Injection i.p. 2 gm/gm



Description

Augmero IV (Meropenem for injection) is a sterile, p-trogen, synthetic, broad spectrum carbapenem antibiotic for administration

Indication

Meropenem for Injection I.V. is indicated as single agent therapy for the treatment of :

- Adult and pediatric patients ($\geq$ months of age) with complicated appendicitis and peritonitis caused by susceptible isolates of viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, pseudomonas aeruginosa, Bacteroides fragilis, B.thetaiotaomicron, and Peptostreptococcus species.
- Adult and pediatric patients ($\geq$ months of age) with complicated, skin and skin structure infections caused by susceptible isolates of Staphylococcus aureus (beta-lactamase and non-beta-lactamase-producing, methicillin-susceptible isolates only)
- Pediatric patients ($\geq$ 3 months of age) with bacterial meningitis caused by susceptible isolates of S. pneumoniae, Haemophilus influenzae (beta-lactamase- and non-beta-lactamase-producing isolates.)

Mechanism of action:

Augmero has bactericidal action by interfering with bacterial cell wall synthesis of both gram positive and gram negative bacteria.

Dosage:

Patient	Indication	Dosage	Duration
Adult	Intra Abdominal Infection	1g 8 hourly	7-14 days
	Nosocomial Pneumonia	1g 8 hourly	4-7 days
	Skin or Soft tissue infection	500 mg- 1 gm 8 hourly	7-10 days
	Cystic Fibrosis	2 g 8 hourly	7- 10 days
	Meningitis	2g 8 hourly	7-21 days
	MIC value >4 mg/ml	2g 8 hourly	7-21 days
Renal Adult	CrCl 26-50 ml/min	1g 12 hourly	-
	CrCl 10- 25 ml/min	500 mg 12 hourly	-
	CrCl <9 ml/min	500 mg 24 hourly	-
Pediatric	Intra Abdominal Infection	20 mg/kg 8 hourly	-
	Meningitis	40 mg/kg 8 hourly	-
	Skin and skin Structure infection	10 mg/kg 8 hourly	-

Strength: Augmero is available in 1 gm and 2 gm strength with WFI

- Note:**
- Meropenem 2 gm Q8H prolonged therapy infused over 3 hours
 - Studies have demonstrated that three hour infusion improved the cumulative probability of target attainment compared to 30 minutes intermittent administration.
 - Demonstrated the successful and safe utilization of maximal daily doses of 9000 mg for meropenem and 6000 mg for doripenem in patients with Cystic Fibrosis, when administered by 3- and 4 - hour prolonged infusions, respectively.

Mkted. By:

Augurs Healthcare

Corp office : Kaiser - Joseph - Str.245,
79098 Freiburg I. Br.(Germany)

Regd. Office: C-17, Vibhuti Khand- 226016

✉ Email - wecare@augurshealthcare.com

Chemist 1.....2.....

Name of Company Rep.....

Mobile no.....